Pliant Therapeutics Inc
PLRX1.140USD
+0.050+4.59%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
70.05MCap. mercado
PérdidaP/E TTM
Más Datos de Pliant Therapeutics Inc Compañía
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Información de Pliant Therapeutics Inc
Símbolo de cotizaciónPLRX
Nombre de la empresaPliant Therapeutics Inc
Fecha de salida a bolsaJun 03, 2020
Director ejecutivoCoulie (Bernard J)
Número de empleados171
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 03
Dirección331 Oyster Point Boulevard
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16504816770
Sitio Webhttps://pliantrx.com/
Símbolo de cotizaciónPLRX
Fecha de salida a bolsaJun 03, 2020
Director ejecutivoCoulie (Bernard J)
Ejecutivos de Pliant Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
616.26K
-89375.00%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-15713.00%
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Keith Cummings, M.D.
Dr. Keith Cummings, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Gayle Crowell
Ms. Gayle Crowell
Independent Director
Independent Director
--
--
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
616.26K
-89375.00%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-15713.00%
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
FY2024
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: mié., 4 de feb
Actualizado: mié., 4 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Tang Capital Management, LLC
9.77%
Woodline Partners LP
7.33%
Point72 Asset Management, L.P.
7.06%
Morgan Stanley & Co. LLC
5.69%
Citadel Advisors LLC
4.94%
Otro
65.21%
Accionistas
Accionistas
Proporción
Tang Capital Management, LLC
9.77%
Woodline Partners LP
7.33%
Point72 Asset Management, L.P.
7.06%
Morgan Stanley & Co. LLC
5.69%
Citadel Advisors LLC
4.94%
Otro
65.21%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
39.23%
Investment Advisor
22.12%
Investment Advisor/Hedge Fund
12.57%
Research Firm
12.08%
Individual Investor
2.40%
Family Office
0.87%
Venture Capital
0.76%
Private Equity
0.04%
Bank and Trust
0.02%
Otro
9.92%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
358
52.26M
85.04%
-35.89M
2025Q3
356
52.49M
85.42%
-37.39M
2025Q2
374
62.63M
102.02%
-15.09M
2025Q1
390
63.45M
103.37%
-12.99M
2024Q4
392
71.13M
116.20%
-8.66M
2024Q3
388
69.61M
114.50%
-7.63M
2024Q2
375
69.93M
115.87%
-7.66M
2024Q1
371
73.36M
121.74%
-3.24M
2023Q4
362
70.03M
116.83%
-95.89K
2023Q3
356
64.13M
107.25%
-2.06M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Tang Capital Management, LLC
6.00M
9.77%
+3.45K
+0.06%
Sep 30, 2025
Woodline Partners LP
4.50M
7.33%
+2.16M
+91.81%
Sep 30, 2025
Point72 Asset Management, L.P.
4.34M
7.06%
+4.34M
--
Sep 30, 2025
Morgan Stanley & Co. LLC
3.50M
5.69%
+1.50M
+75.33%
Sep 30, 2025
Citadel Advisors LLC
2.34M
3.81%
-16.43K
-0.70%
Sep 30, 2025
Blue Owl Capital Holdings LP
2.97M
4.83%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
2.78M
4.52%
-226.41K
-7.54%
Sep 30, 2025
Acadian Asset Management LLC
2.37M
3.86%
+739.13K
+45.33%
Sep 30, 2025
J.P. Morgan Securities LLC
2.13M
3.46%
+171.21K
+8.76%
Sep 30, 2025
Two Sigma Investments, LP
1.86M
3.02%
+1.11M
+148.96%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Humankind US Stock ETF
0%
iShares Morningstar Small-Cap Value ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
ProShares Ultra Nasdaq Biotechnology
Proporción0.01%
iShares Biotechnology ETF
Proporción0.01%
Invesco Nasdaq Biotechnology ETF
Proporción0.01%
DFA Dimensional US Core Equity Market ETF
Proporción0%
Schwab U.S. Small-Cap ETF
Proporción0%
Global X Russell 2000 Covered Call ETF
Proporción0%
Humankind US Stock ETF
Proporción0%
iShares Morningstar Small-Cap Value ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
